Praecis Pharmaceuticals has submitted an Investigational New Drugapplication to the US Food and Drug Administration, seeking approval to begin clinical trials of Apan, its new drug drug for Alzheimer's disease. The firm said that preclinical trials have shown that Apan inhibits the accumulation of beta amyloid in the brain, one of the hallmarks of AD which is associated with toxicity to nerve cells. Praecis also said Apan increases levels of beta amyloid in the cerebrospinal fluid.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze